Sign in Subscribe
United States. Securities and Exchange Commission

Fate Therapeutics Inc. Submits SEC Filing

Strategic Insights

— 1 min read

According to a recent SEC filing, Fate Therapeutics Inc., a biopharmaceutical company, has submitted a report to the U.S. Securities and Exchange Commission on January 11, 2023. The company, which specializes in biological products, has reported one document filed with the form. This filing is a requirement for publicly-traded companies, specifically for directors, officers, or owners of more than 10% of a class of equity securities registered under Section 12 of the '34 Act.

Key Takeaways:

  • Fate Therapeutics Inc. submitted a SEC filing on January 11, 2023, which is a requirement for publicly-traded companies.
  • The company specializes in biological products, specifically with an SIC code of 2836.
  • The filing was made on Form 4, which reports changes in ownership and purchases/sales of equity securities.
  • The company's contact information is 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131, with a phone number of 858.875.1803.
  • The filing contains information on the reporting person's relationship to the company and purchases/sales of equity securities.
  • Fate Therapeutics Inc. is a leading biopharmaceutical company in the biotechnology industry.

Statistics:

  • The company has submitted one document with the SEC filing.
  • The filing was made on January 11, 2023, exactly one week after the reporting deadline.
  • The company's SIC code is 2836, which categorizes it as a biological products manufacturer.
  • The company's contact information includes an address in San Diego, CA, and a phone number.

Sources:

  • NewsRx (2023, January 25). Fate Therapeutics Inc. Submits SEC Filing. Biotech Week.
  • Fate Therapeutics Inc. (2023) Form 4: Statement of changes in beneficial ownership of securities. Obtained from the SEC website at https://www.sec.gov/Archives/edgar/data/1434316/0001209191-23-002974-index.html

Read more